Avicanna Expands Epilepsy Research Program with New Collaboration with Canadian Business Journal University of Toronto

Dr. Mac Burnham’s team will investigate a unique combination of Avicanna drug candidates and cannabinoids in preclinical models of seizures.

Avicanna further expands current research and commercial focus in epilepsy, supported by current medical cannabis sales and ongoing research with UHN

TORONTO, September 15, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), an international commercial-stage biopharmaceutical company focused on the commercialization of evidence-based cannabinoid-based products, expands research collaboration I am pleased to announce that A new collaboration with the University of Toronto and his Dr. Mac Burnham research team is investigating the efficacy of a unique formulation of Avicanna in preclinical models of epilepsy.

New joint research with the University of Toronto

A collaborative study led by Dr. Mac Burnham’s team will investigate the efficacy of Avicanna drug candidates, including AVCN319302, in animal models of epilepsy. In addition, collaborative research will assess the anti-seizure properties of rare cannabinoids, alone and in combination. Dr. Burnham is Emeritus Professor of Pharmacology and Toxicology at the University of Toronto’s Temati School of Medicine, and he is Co-Director of EpLink, an epilepsy research program at the Ontario Brain Institute. With his over 150 publications, he has made significant contributions to the advancement of antiepileptic therapy.

According to Dr. Burnham, “Cannabinoids, both alone and in combination, are some of the most promising antiepileptic drugs I’ve seen in years of research.”

Ongoing research collaboration with University Health Network

The study by Dr. Burnham’s team builds on existing collaborations with the University Health Network and Dr. Peter Karen, Professor of Medicine and Physiology at Temati College of Medicine and Senior Scientist at the Western Institute of Toronto. Extend the

A previously reported electrophysiological study on seizure-induced wild-type cortical slices showed that Avicanna’s proprietary drug candidate, AVCN319302, had a significant anticonvulsant effect and was associated with seizure induction in patients diagnosed with refractory epilepsy and have demonstrated strong potential for treating patients with sudden and unexpected risks of sexual harassment. death.

“We are pleased to continue to expand our research on cannabinoids and their anti-epileptic properties in the field of epilepsy and to work with key Canadian institutions and key opinion leaders. We are also excited about the early acceptance rate of RHO Phyto Micro Drop 50 CBD).Such early acceptance will also provide real-world data and evidence.Combining real-world evidence with ongoing collaborative research. , will allow us to further develop our drug pipeline and further advance our drug candidates in the epilepsy space.”

About Avicanna

Avicanna is a commercial-stage, international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for global medical and pharmaceutical market segments. Avicanna has an established scientific platform, including R&D and clinical development, leading to the commercialization of over 30 products in various market segments.

Medical cannabis and wellness products: Marketed under the RHO Phyto™ brand, these medical and wellness products are pharmaceutical grade cannabinoid products containing varying ratios of cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”). The product portfolio includes a complete formulary of products including oral, sublingual, topical, and transdermal delivery, with preclinical data-backed dosing, enhanced absorption and stability studies. It is Formularies are marketed with consumer, patient and healthcare professional education and training.

Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of indication-specific, patent-pending drug candidates in various stages of clinical development and commercialization Did. These cannabinoid-based drug candidates seek to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna’s first drug (Trunerox™) is in the drug registration stage in South America.

Click to watch Avicanna’s Corporate Video 2022

SOURCE Avicanna Co., Ltd.

stay connected

For more information on Avicanna, please visit www.avicanna.com. Email Ivana Maric. [email protected] or follow us on social media LinkedIn, twitter, Facebook Also Instagram.

We will post updates through our official videos. Youtube channel.

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Any forward-looking information contained in this news release may be interpreted as , and may be identified using words such as “believe”. , “intends”, “plans”, “forecasts”, “plans”, “estimates”, “outlooks” and other similar expressions. Forward-looking information contained in this news release includes, but is not limited to, related statements. Although we believe that the expectations and assumptions upon which such forward-looking information is based are reasonable, we cannot give any assurance that the forward-looking information will prove to be correct. You should not place undue reliance on information. Actual results and deployment may differ materially from those envisioned in these statements. Forward-looking information is subject to various risks and uncertainties that could cause actual events or results to differ materially from those projected by the forward-looking information. Such risks and uncertainties include current and future market conditions, including the market price of our common stock, and the risk factors described in our Annual Information Form filed on March 31, 2022. including but not limited to. Available from his SEDAR company profile at www.sedar.com. Statements in this news release are current as of the date of this release. We disclaim any intention or obligation to update any forward-looking information, whether as a result of new information, future events, results or otherwise, except as required by applicable securities laws.

CBJ Newsmaker